HuGE Literature Finder
Records
1
-
11
| TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. Cancer medicine 2021 Nov . Grote Isabel, Bartels Stephan, Kandt Leonie, Bollmann Laura, Christgen Henriette, Gronewold Malte, Raap Mieke, Lehmann Ulrich, Gluz Oleg, Nitz Ulrike, Kuemmel Sherko, Zu Eulenburg Christine, Braun Michael, Aktas Bahriye, Grischke Eva-Maria, Schumacher Claudia, Luedtke-Heckenkamp Kerstin, Kates Ronald, Wuerstlein Rachel, Graeser Monika, Harbeck Nadia, Christgen Matthias, Kreipe Ha |
| TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. NPJ breast cancer 2021 Apr 7 (1): 43. da Silva Edaise M, Selenica Pier, Vahdatinia Mahsa, Pareja Fresia, Da Cruz Paula Arnaud, Ferrando Lorenzo, Gazzo Andrea M, Dopeso Higinio, Ross Dara S, Bakhteri Ariya, Riaz Nadeem, Chandarlapaty Sarat, Razavi Pedram, Norton Larry, Wen Hannah Y, Brogi Edi, Weigelt Britta, Zhang Hong, Reis-Filho Jorge |
| Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients. Scientific reports 2021 Mar 11 (1): 6761. Muendlein Axel, Geiger Kathrin, Gaenger Stella, Dechow Tobias, Nonnenbroich Christoph, Leiherer Andreas, Drexel Heinz, Gaumann Andreas, Jagla Wolfgang, Winder Thomas, Mayer Frank, Decker Thom |
| The Association of IL-1 and HRAS Gene Polymorphisms with Breast Cancer Susceptibility in a Jordanian Population of Arab Descent: A Genotype-Phenotype Study. Cancers 2020 Jan 12 (2): . Al-Eitan Laith N, Al-Ahmad Bashar H, Almomani Fouad |
| Molecular characterization of metaplastic breast carcinoma via next-generation sequencing. Human pathology 2019 Apr 86 85-92. Zhai Jing, Giannini Gabriel, Ewalt Mark D, Zhang Elizabeth Y, Invernizzi Marta, Niland Joyce, Lai Lily |
| Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology 2018 01 29 (1): 145-153. Fribbens C, Garcia Murillas I, Beaney M, Hrebien S, O'Leary B, Kilburn L, Howarth K, Epstein M, Green E, Rosenfeld N, Ring A, Johnston S, Turner |
| Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer. Oncotarget 2016 Nov . Zhang Tongtong, Li Qing, Chen Shanshan, Luo Yang, Fan Ying, Xu Bing |
| Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas. Neoplasia (New York, N.Y.) 2016 Apr 18 (4): 253-63. Myers Meagan B, Banda Malathi, McKim Karen L, Wang Yiying, Powell Michael J, Parsons Barbara |
| Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Apr . Dalin Martin G, Desrichard Alexis, Katabi Nora, Makarov Vladimir, Walsh Logan A, Lee Ken-Wing, Wang Qingguo, Armenia Joshua, West Lyndsay, Dogan Snjezana, Wang Lu, Ramaswami Deepa, Ho Alan L, Ganly Ian, Solit David, Berger Michael F, Schultz Nikolaus, Reis-Filho Jorge S, Chan Timothy A, Morris Luc |
| Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations. British journal of cancer 2014 Dec 111 (12): 2351-60. Deb S, Wong S Q, Li J, Do H, Weiss J, Byrne D, Chakrabarti A, Bosma T, , Fellowes A, Dobrovic A, Fox S |
| Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients. Asian Pacific journal of cancer prevention : APJCP 2012 13 (11): 5599-603. Tong Lin, Yang Xue-Xi, Liu Min-Feng, Yao Guang-Yu, Dong Jian-Yu, Ye Chang-Sheng, Li Mi |
- Page last reviewed:Jul 25, 2022
- Page last updated:Nov 28, 2022
- Content source: